Male Stress Urinary Incontinence Market Size & Share 2026-2035

Male Stress Urinary Incontinence Market Size

The global male stress urinary incontinence market is estimated at USD 834.7 million in 2025 and is projected to reach USD 1.6 billion by 2035, expanding at approximately 6.7% CAGR during 2026–2035.

Male SUI principally follows impaired urethral sphincter function after radical prostatectomy; radiation, other prostate interventions, trauma, and neurological conditions can also contribute. The market spans implantable surgical solutions-artificial urinary sphincters (AUS), male slings, and adjustable continence balloons-and non-surgical management through condom catheters and penile clamps. That clinical distinction matters commercially: implantable devices address durable restoration of continence, whereas external devices provide conservative or interim leakage management.

The clinical funnel is substantial, but conversion remains limited. GLOBOCAN estimated 1,546,112 new prostate cancer cases globally in 2024, while the Lancet Commission projected annual cases could approach 2.9 million by 2040. ^{[1]The Lancet - The Lancet Commission on Prostate Cancer: Planning for the Surge in Cases, 2024 - thelancet.com} In the United States, an estimated 280,404-362,839 men with persistent SUI could benefit from procedural intervention, yet only 6%-12% undergo an SUI-related procedure. ^{[2]JU Open Plus - Quantifying the Number of US Men With Incident Persistent Stress Urinary Incontinence, 2024 - doi.org} The market therefore depends as much on referral, counseling, reimbursement, and specialist capacity as on disease incidence.

The key boundary condition is access. Surgical devices create most market value, but their uptake requires trained implanting surgeons, a funded pathway, and patients willing to return for treatment after cancer care. Non-surgical products partly protect demand where those conditions are absent, but do not remove the conversion constraint. Growth should consequently be strongest where cancer detection, specialist capacity, and payment coverage develop together, rather than wherever prostate cancer prevalence rises in isolation.

Key Drivers

Rising prevalence of male SUI (post-prostatectomy dominance)

Post-prostatectomy incontinence is the central demand generator. Persistent SUI has been estimated at 23.2% after radical prostatectomy and at up to 30.0% following prostatectomy with adjuvant radiotherapy. The higher burden associated with combined treatment is consequential because radiation-exposed patients can have more complex tissue conditions and may require more intensive specialist evaluation. A German population analysis found a widening disconnect between prostatectomy volume and incontinence-surgery use, indicating that the untreated cohort is not simply a residual pool of patients unsuitable for intervention.

Functionally significant leakage also affects work and physical function, strengthening the case for treatment once patients reach a specialist pathway. For manufacturers, the practical opportunity lies in improving identification and referral after prostate cancer treatment, not in assuming that every incident case converts to an implant.

Technological advancements in devices and surgical techniques

AUS remains the reference option for moderate-to-severe SUI because its evidence base extends from prospective outcomes to long-term device-survival data. In the 115-patient AUSCO study, 94% of implanted men achieved at least a 50% improvement in 24-hour pad weight at one year and 60% were pad-free. ^{[3]Urology Times - Artificial Urinary Sphincter for SUI Shows Safety, Efficacy in Prospective Study, 2025 - urologytimes.com} A Mayo Clinic cohort reported secondary-surgery-free survival of 72% at five years and 56% at 10 years, making revision risk a material part of lifetime treatment economics.

Device choice has become more differentiated. Five-year evidence supports the AdVance XP sling in appropriately selected mild-to-moderate cases, while European multicenter data show that ATOMS can offer an adjustable, non-pump option,. Comparative evidence indicates different trade-offs among dryness, improvement, and explantation outcomes rather than a single modality that dominates every patient profile. UroMems received FDA IDE approval and French ANSM clearance in July 2025 to begin the SOPHIA2 pivotal trial of its automated UroActive AUS, a development aimed at reducing reliance on manual pump operation.

Growing incidence of prostate cancer

Prostate cancer is the second most commonly diagnosed cancer in men, and its case growth enlarges the downstream pool requiring post-treatment continence management. Global absolute case numbers rose 188.85% between 1990 and 2021, according to a Global Burden of Disease analysis. In the United States, incidence rose 3.0% annually between 2014 and 2021. These trends do not translate one-for-one into SUI procedures because treatment modality and continence recovery vary, but they support a durable flow of men requiring assessment after prostate treatment.

The effect is especially relevant in markets where detection and curative treatment capacity are expanding. The distinction between incident cancer diagnoses and implant demand remains important: access to radical prostatectomy, survivorship follow-up, and reconstructive urology determines whether epidemiology becomes a device procedure.

Key Restraints

High procedural cost

Cost can delay or prevent escalation from conservative management to surgery. AUS implantation combines device, surgeon, anesthesia, and facility costs and has been identified as the highest-cost surgical option in the post-prostatectomy pathway. Although Canadian economic analysis found that a higher initial AUS cost can be offset by its long-term performance relative to a sling when revision costs are considered, the up-front budget hurdle remains. Medicaid coverage is widespread for AUS and slings in the United States, but median physician payment levels can still constrain delivery of device-intensive procedures in resource-limited settings.

Affordability intersects with stigma and care-seeking. A study of men with urinary incontinence found that embarrassment and normalization of symptoms materially deter treatment-seeking. In lower-funded systems, this behavioral barrier is reinforced by limited reimbursement and scarce implanting capacity, increasing reliance on lower-cost external management. The restraint therefore changes product mix as well as total market growth.

Innovation can ease that constraint only when it improves the care pathway as well as the device. Strong AUS outcomes support continued use in complex disease,, but future automated systems still need pivotal evidence and successful commercialization before they can alter routine practice. The near-term commercial priority is consequently evidence-supported patient selection and procedure delivery in settings that can absorb implant cost, coupled with lower-barrier management options where reimbursement remains incomplete.

Male Stress Urinary Incontinence Market Segment Analysis

By Product

Surgical devices generate USD 552.6 million in 2025, or 66.2% of the market, and are forecast to grow at approximately 6.9% CAGR. Their value concentration reflects both clinical use in persistent moderate-to-severe disease and the higher revenue per implant. AUS is the largest surgical category at USD 317.1 million, followed by male slings at USD 202.1 million and adjustable continence balloons at USD 33.5 million.

AUS is forecast to grow at approximately 6.6% CAGR. Its clinical position is reinforced by prospective effectiveness data and by long-term evidence that makes revision burden visible in pre-procedure counseling,. The segment's constraint is not lack of clinical relevance; it is the need for manual operation, surgical expertise, and lifecycle management. Male slings are forecast at approximately 7.0% CAGR because they address selected mild-to-moderate cases without a pump. Their appeal rests on matching residual sphincter function and severity to a less complex intervention, rather than substituting indiscriminately for AUS,.

Adjustable continence balloons are projected to grow at approximately 7.8% CAGR from a smaller base. Evidence for ProACT shows a meaningful but complication-sensitive clinical profile, while VICTO data support continued development of adjustable continence approaches,. Their passive operation and office-based adjustability can be relevant for patients unable or unwilling to manipulate an AUS pump, but complication and explantation risk constrain broad substitution.

Non-surgical devices represent USD 282.1 million, or 33.8%, of 2025 revenue, and are forecast to expand at approximately 6.2% CAGR. Condom catheters account for USD 221.2 million, or 78.4% of this segment, while penile clamps account for USD 60.9 million. These categories serve patients who defer surgery, are unsuitable for it, or require ongoing management of residual leakage. Their recurring utilization gives the segment a different economic profile from implants, but it does not make them clinically equivalent to restorative surgery. Clinical guidance continues to place conservative and surgical options within a patient-specific pathway after prostate treatment.

By End Use

Hospitals account for USD 405.4 million in 2025, or 48.6% of market revenue, supported by anesthesia capability, reconstructive expertise, and management of complex primary and revision cases. ASCs account for USD 189.8 million and are forecast to grow at approximately 7.2% CAGR, the fastest rate among end users. Site-of-care migration is most credible for selected outpatient procedures; it depends on surgeon experience, payer policy, anesthesia protocols, and the patient's clinical complexity rather than a wholesale transfer of all implant activity.

Urology clinics generate USD 153.4 million and are forecast at approximately 6.9% CAGR. They are central to diagnosis, counseling, follow-up, and adjustment of adjustable systems. Other end users, including long-term care, home care, and rehabilitation settings, account for USD 86.0 million and grow more slowly at approximately 5.4% CAGR because demand is weighted toward lower-value external devices.

The ASC forecast of approximately 7.2% CAGR signals a potential access lever, not merely a change in venue. If appropriately selected sling, balloon, and AUS cases can move to outpatient settings, lower facility burden may improve payer acceptance and patient convenience. Hospitals will nevertheless retain complex revisions and high-risk cases, preserving a dual-channel model instead of a simple hospital-to-ASC replacement.

Male Stress Urinary Incontinence Market Regional Analysis

North America

North America is estimated at USD 388.6 million in 2025, or 46.6% of global revenue, and is projected to reach USD 725.0 million by 2035 at approximately 6.5% CAGR. The United States contributes USD 360.0 million in 2025 and is expected to reach USD 667.1 million by 2035; Canada contributes USD 28.7 million in 2025 and is forecast to grow at approximately 7.4% CAGR. The region combines high prostate cancer detection, mature specialist capacity, and a defined reimbursement environment. US procedure coverage and coding support access, although payment adequacy and patient counseling remain operational constraints. ^{[4]Urology Practice - Does Medicaid Cover Artificial Urinary Sphincter and Male Slings? A State-by-State Analysis, 2023 - pmc.ncbi.nlm.nih.gov}

Europe

Europe generates USD 200.0 million in 2025 and is forecast at approximately 5.9% CAGR. Germany, the UK, France, Spain, Italy, and the Netherlands anchor demand through established urology centers and public-system delivery. Germany's underutilization of incontinence surgery despite increasing prostatectomy activity illustrates the difference between a clinically mature market and a fully penetrated one. Public budget discipline and local capacity can moderate procedure growth even where specialist evidence and technology are available.

Asia Pacific

Asia Pacific is valued at USD 166.5 million in 2025 and is projected to grow fastest, at approximately 7.7% CAGR. Japan and Australia provide relatively mature surgical-device settings; China, India, and South Korea combine expanding cancer detection with uneven access to reconstructive urology. The opportunity is driven by developing care infrastructure as much as by disease incidence. Australia/New Zealand and other higher-incidence settings demonstrate the importance of diagnosis, but broader regional conversion will depend on training, local registration, and affordability.

Latin America

Latin America accounts for USD 47.6 million in 2025 and is forecast to grow at approximately 6.8% CAGR. Brazil, Mexico, and Argentina lead regional demand. GLOBOCAN estimated 215,448 new prostate cancer cases in Latin America and the Caribbean in 2024. Private-sector specialist care can support implant adoption, but uneven reimbursement and geographic concentration of surgical services preserve a larger role for non-surgical management.

Middle East & Africa

Middle East & Africa is estimated at USD 32.0 million in 2025 and is forecast to grow at approximately 7.2% CAGR. South Africa, Saudi Arabia, and the UAE are the principal markets. Gulf investment in tertiary care can create pockets of advanced implant access, whereas the wider region remains constrained by payment capacity and specialist distribution. The growth rate should therefore be interpreted against a low revenue base rather than as evidence of uniform regional availability.

Latin America and Middle East & Africa offer selective, not homogeneous, expansion. High-incidence cancer populations alone do not resolve the cost and capability barriers that favor conservative devices. Manufacturers seeking growth outside mature markets will need local regulatory, distributor, and training execution, while preserving product configurations that fit the affordability and follow-up conditions of each country.

Male Stress Urinary Incontinence Market Share & Competitive Landscape

Competition is differentiated by modality, clinical evidence, and route to market. Boston Scientific is positioned across AUS and male slings, with prospective AUS evidence and AdVance XP data underpinning its surgical franchise,. Coloplast participates in surgical and non-surgical management; its February 2026 acquisition of Uromedica added ProACT adjustable-balloon therapy to its men's urology portfolio. ^{[5]Davis Polk - Coloplast Acquisition of Uromedica, February 2026 - davispolk.com} A.M.I. GmbH competes through the ATOMS adjustable sling, for which European multicenter outcomes support a distinct non-pump proposition.

Promedon supplies adjustable continence technologies, including VICTO, with published mid-term clinical outcomes. Neomedic's Remeex Male Sling, CL Medical's I-STOP TOMS, and Zephyr Surgical Implants' ZSI 375 PF address specialized sling or AUS niches, particularly through specialist-center adoption. Rigicon, Inc. competes in AUS development and market access, while the absence of independently corroborated evidence in the supplied package limits assessment of its product-performance claims. Becton, Dickinson and Company and Teleflex participate through external-catheter offerings, where institutional purchasing relationships and availability matter more than implant-surgeon training.

The competitive advantage is consequently not reducible to device design. Implant suppliers need clinical evidence, surgeon education, revision support, and market-access capability; external-management suppliers compete through reliability, fit, supply continuity, and institutional procurement. Portfolio breadth can be valuable when it allows a supplier to retain patients across conservative management and procedural escalation, but it does not eliminate the need for device-specific evidence.

Recent Industry Developments

July 2025 - UroMems received FDA IDE approval and French ANSM clearance for SOPHIA2. The clearances enabled the pivotal multicenter study of the UroActive automated AUS, designed to respond to changes in intra-abdominal pressure without manual pump actuation.

2025 - AUSCO prospective trial results were presented at the AUA Annual Meeting. The 115-patient, 17-site study reported 94% achievement of at least 50% improvement in 24-hour pad weight and 60% pad-free continence at one year after AUS implantation.

February 2026 - Coloplast completed its acquisition of Uromedica. The transaction brought ProACT adjustable continence therapy into Coloplast's portfolio.